Copyright
©2011 Baishideng Publishing Group Co.
World J Clin Oncol. May 10, 2011; 2(5): 229-236
Published online May 10, 2011. doi: 10.5306/wjco.v2.i5.229
Published online May 10, 2011. doi: 10.5306/wjco.v2.i5.229
Figure 7 Monitoring therapeutic effect in liver metastases due to GIST gastrointestinal stromal tumor using Gleevec (imatinib mesylate).
A, B: Before chemotherapy. A: CECT demonstrated bull’s eye like low density in the liver, which was consistent with metastases; B: The metastatic tumor shown as an FDG-avid mass; C, D: After chemotherapy. (C) CECT shows similar mass before chemotherapy although (D) fluorodeoxyglucose (FDG) uptake significantly decreased. FDG-PET may more correctly reflect the therapeutic effect than CECT.
- Citation: Murakami K. FDG-PET for hepatobiliary and pancreatic cancer: Advances and current limitations. World J Clin Oncol 2011; 2(5): 229-236
- URL: https://www.wjgnet.com/2218-4333/full/v2/i5/229.htm
- DOI: https://dx.doi.org/10.5306/wjco.v2.i5.229